{
  "id": 5416477,
  "title": "How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?",
  "url": "https://urgent.news/2026/09/02/how-is-boston-scientifics-stock-performance-compared-to-other-medical",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-02T13:23:28.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/boston-scientifics-stock-performance-compared-132328388.html"
  },
  "original_language": "en",
  "account": "Boston Scientific Corporation (BSX), a global medical technology leader with a market cap of $69.7 billion, specializes in high-performance devices and therapies for complex medical conditions. Its portfolio spans cardiovascular, respiratory, digestive, oncological, neurological, and urological areas. Recently, BSX stock has underperformed compared to the broader healthcare sector. On a year-to-date basis, the stock has experienced a 49.6% decline, trailing the 6.5% gain of the State Street SPDR S&P Health Care Equipment ETF (XHE). Furthermore, BSX shares have fallen 54.4% over the past year, contrasting with XHE's 14.4% increase. Despite reporting Q2 2026 adjusted EPS of $0.86, better than expected, BSX shares fell on Jul. 29 after the company lowered its adjusted EPS outlook to $3.28 - $3.32, missing analyst estimates. Reasons cited include weaker Watchman demand and increased competition in U.S. electrophysiology. BSX's stock trades below both its 50-day and 200-day moving averages. In contrast, Stryker Corporation (SYK) has seen a less severe decline, with a YTD drop of 9.5% and a 52-week decrease of 18.5%. Analysts maintain a strong buy rating on BSX, with a mean price target of $61.04, representing a 27% premium to current levels.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}